MX2020006905A - Composiciones farmaceuticas liquidas orales de aminosalicilatos. - Google Patents

Composiciones farmaceuticas liquidas orales de aminosalicilatos.

Info

Publication number
MX2020006905A
MX2020006905A MX2020006905A MX2020006905A MX2020006905A MX 2020006905 A MX2020006905 A MX 2020006905A MX 2020006905 A MX2020006905 A MX 2020006905A MX 2020006905 A MX2020006905 A MX 2020006905A MX 2020006905 A MX2020006905 A MX 2020006905A
Authority
MX
Mexico
Prior art keywords
pharmaceutical compositions
liquid pharmaceutical
oral liquid
aminosalicylates
aminosalicylate
Prior art date
Application number
MX2020006905A
Other languages
English (en)
Inventor
Alfred Chi - Yeh LIANG
Eric Ehrnsperger
Xiaohong Shen
Original Assignee
Ferring Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ferring Bv filed Critical Ferring Bv
Publication of MX2020006905A publication Critical patent/MX2020006905A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/606—Salicylic acid; Derivatives thereof having amino groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dispersion Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

En el presente documento, se describen composiciones farmacéuticas líquidas orales para la administración oral de un aminosalicilato, así como métodos de preparación de dichas composiciones farmacéuticas líquidas orales y métodos terapéuticos para usarlas. Las composiciones farmacéuticas líquidas orales comprenden micropartículas de liberación prolongada formuladas con un aminosalicilato, en donde las micropartículas de liberación prolongada están dotadas de un recubrimiento externo de liberación retardada.
MX2020006905A 2018-01-03 2019-01-02 Composiciones farmaceuticas liquidas orales de aminosalicilatos. MX2020006905A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862613198P 2018-01-03 2018-01-03
PCT/US2019/012032 WO2019136053A1 (en) 2018-01-03 2019-01-02 Oral liquid pharmaceutical compositions of aminosalicylates

Publications (1)

Publication Number Publication Date
MX2020006905A true MX2020006905A (es) 2020-09-09

Family

ID=65324535

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020006905A MX2020006905A (es) 2018-01-03 2019-01-02 Composiciones farmaceuticas liquidas orales de aminosalicilatos.

Country Status (10)

Country Link
US (1) US20210077415A1 (es)
EP (1) EP3735219A1 (es)
JP (1) JP7438113B2 (es)
KR (1) KR20200107998A (es)
CN (1) CN111954517A (es)
AU (1) AU2019205192A1 (es)
BR (1) BR112020013398A2 (es)
CA (1) CA3086767A1 (es)
MX (1) MX2020006905A (es)
WO (1) WO2019136053A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112402376A (zh) * 2019-08-22 2021-02-26 上海上药信谊药厂有限公司 一种结肠靶向的柳氮磺吡啶口服混悬剂及其制备方法
KR20220048265A (ko) 2020-10-12 2022-04-19 문경주 6가 크롬 용출이 없는 저시멘트계 무기결합재 조성물

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4328069A1 (de) * 1993-08-20 1995-02-23 Henning Berlin Gmbh Mikropartikel, Verfahren zu ihrer Herstellung und ihre Verwendung zur Herstellung von Arzneimitteln
DE19732903A1 (de) * 1997-07-30 1999-02-04 Falk Pharma Gmbh Pellet-Formulierung zur Behandlung des Intestinaltraktes
US7737133B2 (en) * 2003-09-03 2010-06-15 Agi Therapeutics Ltd. Formulations and methods of treating inflammatory bowel disease
WO2005074599A2 (en) * 2004-01-30 2005-08-18 Chemgenex Pharmaceuticals, Inc. Naphthalimide dosing by n-acetyl transferase genotyping
GB2419094A (en) * 2004-10-12 2006-04-19 Sandoz Ag Pharmaceutical composition of unpleasnt tasing active substances
US20060093629A1 (en) * 2004-10-29 2006-05-04 Buehler Gail K Dye-free pharmaceutical suspensions and related methods
US9149439B2 (en) * 2005-03-21 2015-10-06 Sandoz Ag Multi-particulate, modified-release composition
US20080118570A1 (en) * 2006-11-20 2008-05-22 Zhi Liu Polymer coated drug-ion exchange resins and methods
WO2009047802A2 (en) * 2007-10-10 2009-04-16 Lupin Limited Novel colon targeted modified release bioadhesive formulation of 5-amino salicylic acid or its salts and metabolites thereof
US10064836B2 (en) * 2012-08-03 2018-09-04 Tyratech, Inc. Antiparasitic compositions and methods
MX2016014320A (es) * 2014-05-01 2017-05-23 Sun Pharmaceutical Ind Ltd Composiciones de suspension de liberacion prolongada.
US20190008787A1 (en) * 2015-07-17 2019-01-10 BE Pharbel Manufacturing Multilayered pharmaceutically active compound-releasing microparticles in a liquid dosage form

Also Published As

Publication number Publication date
JP7438113B2 (ja) 2024-02-26
EP3735219A1 (en) 2020-11-11
CA3086767A1 (en) 2019-07-11
US20210077415A1 (en) 2021-03-18
WO2019136053A1 (en) 2019-07-11
RU2020123262A (ru) 2022-02-03
CN111954517A (zh) 2020-11-17
JP2021509664A (ja) 2021-04-01
BR112020013398A2 (pt) 2020-12-01
AU2019205192A1 (en) 2020-07-09
KR20200107998A (ko) 2020-09-16

Similar Documents

Publication Publication Date Title
PH12019502058A1 (en) Farnesoid x receptor agonists and uses thereof
EP3840730A4 (en) COMPOSITIONS FOR DELIVERY OF THERAPEUTICS AND METHOD OF USE AND MANUFACTURING THEREOF
PH12020551043A1 (en) Compounds, compositions, and methods for treatment of diseases involving acidic or hypoxic diseased tissues
MX2022007968A (es) Dosificacion de gamma-hidroxibutirato (ghb).
PH12021550605A1 (en) Farnesoid x receptor agonists and uses thereof
PH12019502646A1 (en) Pyrazole magl inhibitors
CR20220215A (es) Heteroaril bifenil amidas para el tratamiento de enfermedades relacionadas con el ligando pd-l1
MX2018012618A (es) Composiciones farmaceuticas orales de mesalazina.
MX2023001963A (es) Composiciones farmaceuticas hipertonicas que contienen un agente quimioprotector antiplatino.
WO2018067520A3 (en) Therapeutic agents and methods:
EP3849404A4 (en) SMALL HIGHLY UNIFORM NANOMEDICAL COMPOSITIONS FOR THERAPEUTIC, IMAGING AND THERANOSTIC APPLICATIONS
CR20220216A (es) Aminas de heteroaril-bifenilo para el tratamiento de enfermedades pd-l1
WO2019087083A3 (en) Oral delivery of glp-1 peptide analogs
PH12021550413A1 (en) Vitamin d pediatric dosage forms, methods of making and using
MX2020011756A (es) Compuesto farmaceutico, sales del mismo, formulaciones del mismo y metodos para hacer y usar el mismo.
MX2020006905A (es) Composiciones farmaceuticas liquidas orales de aminosalicilatos.
MX2017006513A (es) Compuestos de tipo 1,9-diazaespiroundecano con actividad multimodal contra el dolor.
MX2020013389A (es) Composiciones de terlipresina y usos de las mismas.
MX2018010065A (es) Forma de dosificacion oral que comprende rifaximina en forma beta.
IL284132A (en) A pharmaceutical compound, a method for its preparation and its use as a medicinal substance
MX2019015869A (es) Nuevas formulaciones orales de belinostat.
EP3781194A4 (en) COMPOSITIONS AND METHODS FOR SELECTIVE DELIVERY OF THERAPEUTIC AND IMAGING AGENTS
AU2018286535A1 (en) Delayed sustained release pharmaceutical compositions
RS61747B1 (sr) Farmaceutska kompozicija za lečenje konstipacije
MX2018000418A (es) Derivados de amida que tienen actividad multimodal contra el dolor.